Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

T.B. Special Situations

11,271 views

Published on

T.B. Special Situations

  1. 1. PROF. DR. ZAFAR HUSSAIN IQBAL MBBS, DTCD, MRCP, FRCP PROF. OF PULMONOLOGY AIMC / JHL Management of Tuberculosis In Special Situations
  2. 2. Tuberculosis - Global  TB is shadow of poverty  1/3rd of the world population infected (1.7 billion)  10% gets the disease  10 million new cases each year  4 million deaths each year  Crash of Boeing 747 each hour every day  1 untreated pt. infects 10-15 persons per year  WHO declared TB as global emergency 1993
  3. 3. Tuberculosis - Pakistan  Ranks 8th amongst 22 high burden countries  Incidence 181 /100,000  Est. no of new TB cases 297,108  New sputum smear +ve 81 /100,000  Prevalence 329 /100,000  Mortality 40 /100,000  New MDR Tb cases 3.2 % (WHO Global TB Report Published in 2009 – Data of 2007)
  4. 4. Tuberculosis - Diagnosis Pulmonary TB  Direct sputum smear microscopy - Gold Standard  CXR – unreliable, helpful in smear negative cases  Tuberculin testing – limited value in clinical work  ESR – no diagnostic value  Serological tests  PCR Extra-Pulmonary TB  Tissue smear for AFB and AFB culture  Histology  Clinical setting
  5. 5. Tuberculosis – Treatment New case  Smear positive pulmonary TB  Smear negative pulmonary TB  Extra-pulmonary TB Initial intensive phase – 2 RHEZ Continuation phase – 6 RH or 6 HE Re-treatment  Relapses  Treatment failure  Defaulter Initial phase – 2 RHEZ + S, 1 RHEZ Continuation phase – 5 RHE
  6. 6. Pregnancy • H, R, PZA, E : Safe, No evidence of teratogenecity or congenital malformations • Add Pyridoxine with INH to avoid small risk of CNS damage in infants • Rifampicin : High dose teratogenic in animals • Streptomycin : Ototoxic, may cause deafness in babies, Contraindicated • Capreomycin, Kenamycin, Viomycin • Ethionamide & Prothionamide : Teratogenic
  7. 7. Infants of T.B. mothers & Breast Feeding • Mothers must continue A.T.T during feeding • Child should not be separated • Mother should cover her mouth during cough particularly if smear +ve • INH prophylaxis : 5 mg/Kg 2 months • Do T.T - if –ve, stop INH, give BCG - if +ve, continue INH 4 months, then BCG • Do not give BCG while on INH • INH resistant BCG • Rifampicin + INH – 3 months
  8. 8. Women on O.C.P  Rifampicin: Hepatic enzyme inducer  O.C.P may become ineffective  Rifampicin babies  Extra / alternative protection required  Higher dosage
  9. 9. Renal Impairment - CKD  Acquired Immunodeficiency state - High risk of T.B.  50% Tuberculin -ve  Common in Asian and African origin in UK  Three categories  CKD  Dialysis  Transplant General principle - Standard chemotherapy, standard duration, Dose interval modification Creatinine clearance is a better indicator than serum creatinine
  10. 10. Grades Of Renal Impairment In CKD Stage 1 CKD : Normal CC with structural abnormality Stage 2 CKD : CC 60 – 90ml/ min Stage 3 CKD : CC 30 – 60ml/min Stage 4 CKD : CC 15 – 30ml/min Stage 5 CKD : CC < 15ml/min with or without dialysis
  11. 11. Renal Impairment Rifampicin:  Safe , Active metabolite excreted in bile.  Inactive metabolite (10%) excreted in urine  Use normal dose in all stages INH  Safe, Metabolized in liver .  Add pyridoxine to avoid P.N.  Use normal dose in all stages
  12. 12. Renal Impairment Pyrazinamide  Metabolized in liver  Delayed elimination of drug & metabolites in CKD 4 & 5  Needs dose interval adjustment CKD 1-3 < 50kg : 1.5g daily > 50Kg : 2 g daily CKD 4-5 25-30 mg/Kg 3 x / week
  13. 13. Renal Impairment Ethambutol  Nephrotoxic , Renal excretion - 80% unchanged  Ocular toxicity – dose dependent  Serum monitoring required – should be <1.0ug/ml CKD 1-3 15mg/kg daily CKD 4-5 15-25mg/Kg 3 x week Max 2.5 g
  14. 14. Renal Impairment Amino glycosides – Streptomycin • Nephrotoxic, renal excretion- 80% unchanged • Reduced clearance in elderly • Needs dose interval adjustment in all stages • 12-15mg/Kg - 2 or 3 time/week • Monitor serum levels, ensure trough levels (at 24hrs) of < 2 ugm/ml • New recomandations - avoid Aminoglycosides • Use Moxiflocacin - 400mg daily CKD 1-3
  15. 15. Renal Impairment Prothionamide : Safe, Billiary excretion Thiacetazone, PAS, Cycloserine  Should be avoided  Partially excreted by kidneys
  16. 16. Dose chart of ATT in CKD BTS Guidelines 2010 DRUG Stage 1- 3 CKD Stage 4 - 5 CKD Transplant INH 300mg daily 300mg daily 300mg daily Rifampicin <50 kg:450mg OD >50 Kg:600mg OD <50 kg:450mg OD >50 Kg:600mg OD <50 kg:450mg OD >50 Kg:600mg OD PZA <50 kg: 1.5 G OD >50 Kg: 2 G OD 25 – 30 mg/Kg 3 x/ week <50 kg: 1.5 G OD >50 Kg: 2 OD Ethambutol 15 mg/Kg daily 15 – 25 mg/Kg 3x weekly, Max 2.5G 15 mg/Kg daily Moxifloxacin 400mg daily Not suitable for 3 x weekly 400 mg daily
  17. 17. Chemoprophylaxis in CKD  INH 6 months  RH 3 months  R 4-6months  RZ 2 months  Protective efficiency 60 -65 % with 6H 50 % with 3 RH  Long term use of INH not recommended
  18. 18. ATT in Hemodialysis  Immediately after HD – To avoid premature removal  4- 6 hrs before HD – To reduce toxicity  R & H – Standard daily dose  PZA – Standard dose – 3 x weekly  Ethambutol - Standard dose – 3 x weekly  Avoid Streptomycin
  19. 19. ATT in Renal Transplant  Standard dosage and duration of HRZE  May need modification until normal renal function  Ethambutol can be replaced with Moxifloxacin  Rifampicin Hepatic enzyme inducer – risk of graft rejection Dose adjustment for Ciclosoprin ,Tacrolimus Mycofenolate Double the dose of steroids
  20. 20. ATT Induced Hepatitis • Usually present early but may present any time • More with fixed drug combination than with split regimen • Mild / transient derangement in LFTs is normal (15 – 20 %) • TYPES – Hepatocellular , Cholestatic , Mixed • Check viral serology (B,C) in all patients who develop hepatitis while on ATT
  21. 21. ATT Induced Hepatitis RISK FACTOR • Age >35 years • Female sex • Oriental race (EAST ASIAN) • Pre-existing liver disease • Extensive tuberculosis • High alcohol consumption • Malnutrition and hypo Albuminemia • Other hepatotoxic drugs • Slow Acetylator status • High dosage in relation to body weight
  22. 22. Management Recommendation Of Joint TB Committee Of BTS • ↑ ALT/AST (< Twice normal) - Continue ATT - Check after 2 weeks • ↑ ALT/AST (>Twice normal) - Continue ATT - Check LFTs weekly for 2 weeks - Then every 2 weeks until normal • ↑ ALT/AST (>Thrice normal) + Symptoms - Anorexia, Nausea, Vomiting, Abdominal Pain , Jaundice - STOPATT
  23. 23. Recommendation Of Joint TB Committee Of BTS AST/ALT (>5 time normal) OR ↑ Bilirubin Even If Patient Asymptomatic Stop ATT If patient is smear –ve / Clinically stable - Wait until LFTs are normal - No need for alternate drugs If patient is smear +ve / Clinically unstable - Start Ethambutol, Streptomycin and one of the reserve drugs until LFT‘s are normal - Continue safe drugs until LFTs are normal
  24. 24. Recommendation Of Joint TB Committee When LFT’s are normal • Reintroduce ATT to detect offending drugs • Start with least hepatotoxic one by one INH > RIF > PZA If no reaction • Continue ATT • Stop alternate drugs If reaction has developed • Stop offending drug • Continue remaining drugs • Ensure adequate regimen and duration
  25. 25. HIV - Infected or AIDS  Standard regimen – usually good response  Drug reactions more common  Thiacetazone should be avoided  Prolonged treatment  Patients on Anti-retroviral therapy- high risk of interaction with Rifampicin withhold ATT during this period
  26. 26. SILICOSIS  More prone to develop P.T.B  Difficult to treat - Impaired macrophages function Poor penetration of drug in P.M.F  Hong Kong study – rock islands of Granite 40% suffer from P.T.B  High relapse rate – 22 to 33% : 2 & 5 years  Slower sputum conversion  Standard regimen, longer duration
  27. 27. THANK YOU

×